Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed EBIT for 3 consecutive years, with -$12.8 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 8.96% to -$12.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.6 million through Dec 2025, up 1.0% year-over-year, with the annual reading at -$52.6 million for FY2025, 1.0% up from the prior year.
  • EBIT hit -$12.8 million in Q4 2025 for Camp4 Therapeutics, up from -$13.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$12.3 million in Q3 2023 to a low of -$14.0 million in Q4 2024.
  • Historically, EBIT has averaged -$13.1 million across 3 years, with a median of -$13.1 million in 2025.
  • Biggest five-year swings in EBIT: fell 9.55% in 2024 and later grew 8.96% in 2025.
  • Year by year, EBIT stood at -$13.5 million in 2023, then decreased by 4.14% to -$14.0 million in 2024, then increased by 8.96% to -$12.8 million in 2025.
  • Business Quant data shows EBIT for CAMP at -$12.8 million in Q4 2025, -$13.7 million in Q3 2025, and -$13.0 million in Q2 2025.